anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The aim of this case report is to show the advantages of the extraperitoneal cesarean section (ECS) approach in a pregnant patient with multiple previous abdominal transperitoneal colon surgeries and Crohn's disease. A pregnant nulliparous woman with Crohn's disease was admitted for delivery. After delivery, a large rupture and lesion of the rectum was observed. Suturing of the vagina, rectum and sphincter was performed by an abdominal surgeon. Because of a very large and irregularly shaped rectum rupture, the patient underwent infraumbilical medial laparotomy and sigmoidostomy. After 18 months, the patient started to experience vaginal discharge and Y-shaped rectovaginal fistula was confirmed. Surgical reconstruction was performed. The patient's second pregnancy began one year later. At 38 weeks of pregnancy, elective extraperitoneal cesarean section was performed. A healthy newborn was delivered. Follow-up showed full and fast recovery after the ECS. In cases of pregnant women who have had multiple colon surgeries, gynecology surgeons can choose to perform an ECS to avoid transperitoneal entrance into the abdomen. ECS avoids lysis of postoperative adhesions after repetitive gastrointestinal surgeries, the formation of new adhesions by lysis of the old adhesions, and most importantly, the possibility of colon or small intestine lesions during lysis of dense or firm adhesions.
PURPOSE:To obtain the subject substance, containing phytin or phytic acid extracted from rice, especially a by-product such as rice bran in producing brewed foods as a raw material and their treated substances as an active ingredient and utilizable as a medicine or a food effective in preventing and treating hypertension. CONSTITUTION:An angiotensin converting enzyme inhibitor containing phytin or a phytic acid salt obtained by extracting a by-product such as rice bran in producing brewed foods as a raw material with an acid (not only an inorganic acid but also an organic acid can be used), a salt, etc., or treating the by-product with a protease (e.g. pepsin, trypsin, cathepsin, papain or bromelin) or their treated substances. The inhibitor has effective inhibitory action on angiotensin converting enzymes and extremely high safety. Since the by-product is used, resources can effectively be utilized. The inhibitor can orally be ingested and is advantageous.
The aim of this study is to assess the effectiveness of the influenza vaccine in the T2DM group, T2DM-CKD group, and healthy individuals without DM or CKD as a comparison. Patients with T2DM are characterized by low-grade inflammation, making them susceptible to infections, particularly influenza, leading to increased ICU admissions and mortality rates. Diabetes mellitus is also a major cause of declining kidney function, with complications known as diabetic kidney disease, ultimately progressing to chronic kidney disease, the most common cause of patients undergoing haemodialysis. The vulnerability to influenza infections prompts the recommendation for influenza vaccination in T2DM patients. Chronic kidney disease is a complication of diabetes that becomes intriguing to study regarding the effectiveness of the influenza vaccine in this group. Safety monitoring for all three groups is conducted for one month post-vaccination, assessing local symptoms such as redness at the injection site, pain, and systemic symptoms like fever, diarrhoea, weakness, or fatigue. Information related to influenza vaccine effectiveness is obtained by monitoring flu-like syndrome symptoms at months 1, 3, and 6. The researchers also examine interleukin levels, specifically IL-2 and IL-6, before and after vaccination for one month. This examination aims to understand the dynamic changes in both interleukins since IL-2 plays a role in protecting DM patients from influenza virus infections, particularly in preventing secondary infections like pneumonia.

The researcher's hypothesis is that T2DM-CKD patients will exhibit lower antibody responses compared to uncomplicated T2DM patients, and antibody titters against the influenza virus will decline after six months. This study will contribute valuable insights into the frequency of influenza vaccine administration in T2DM and T2DM-CKD groups, potentially reducing morbidity and mortality rates.
Participants in Phase 2a EC cohorts will receive IV infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight \<80 kg will receive IV infusion of amivantamab 1,050 mg and participants with body weight \>=80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle) followed by additional dosing based on body weight if recommended by CTMT (amivantamab 1750 mg for body weight \<80 kg and 2100 mg for body weight \>=80 kg as IV infusion) every 2 weeks on Days 1 and 15 of 28 day cycle. Phase 2b EC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.
Zolpidem tartrate extended-release tablets were evaluated in three placebo-controlled studies for the treatment of patients with chronic primary insomnia (as defined in the APA Diagnostic and Statistical Manual of Mental Disorders, DSM IV). 

Adult outpatients (18 to 64 years) with primary insomnia (N=212) were evaluated in a double-blind, randomized, parallel-group, 3-week trial comparing zolpidem tartrate extended-release tablets 12.5 mg and placebo. Zolpidem tartrate extended-release tablets 12.5 mg decreased wake time after sleep onset (WASO) for the first 7 hours during the first 2 nights and for the first 5 hours after 2 weeks of treatment. Zolpidem tartrate extended-release tablets 12.5 mg were superior to placebo on objective measures (polysomnography recordings) of sleep induction (by decreasing latency to persistent sleep [LPS]) during the first 2 nights of treatment and after 2 weeks of treatment. Zolpidem tartrate extended-release tablets 12.5 mg were also superior to placebo on the patient reported global impression regarding the aid to sleep after the first 2 nights and after 3 weeks of treatment. 

Elderly outpatients (≥ 65 years) with primary insomnia (N=205) were evaluated in a double-blind, randomized, parallel-group, 3-week trial comparing zolpidem tartrate extended-release tablets 6.25 mg and placebo. Zolpidem tartrate extended-release tablets 6.25 mg decreased wake time after sleep onset (WASO) for the first 6 hours during the first 2 nights and the first 4 hours after 2 weeks of treatment. Zolpidem tartrate extended-release tablets 6.25 mg were superior to placebo on objective measures (polysomnography recordings) of sleep induction (by decreasing LPS) during the first 2 nights of treatment and after 2 weeks on treatment. Zolpidem tartrate extended-release tablets 6.25 mg were superior to placebo on the patient reported global impression regarding the aid to sleep after the first 2 nights and after 3 weeks of treatment. 

In both studies, in patients treated with zolpidem tartrate extended-release tablets, polysomnography showed increased wakefulness at the end of the night compared to placebo-treated patients. 

In a 24-week double-blind, placebo controlled, randomized study in adult outpatients (18 to 64 years) with primary insomnia (N=1025), zolpidem tartrate extended-release tablets 12.5 mg administered as needed (3 to 7 nights per week) was superior to placebo over 24 weeks, on patient global impression regarding aid to sleep, and on patient-reported specific sleep parameters for sleep induction and sleep maintenance with no significant increased frequency of drug intake observed over time.
The active ingredient in mesalamine suppositories, 1000 mg is mesalamine, also known as mesalazine or 5-aminosalicylic acid (5-ASA). Chemically, mesalamine is 5-amino-2-hydroxybenzoic acid, and is classified as an aminosalicylate drug. Each mesalamine suppository contains 1000 mg of mesalamine, USP (micronized) in a base of hard fat.

Mesalamine, USP (micronized) are light tan to pink colored, needle-shaped crystals. Color may darken on exposure to air. It is odorless or may have a slight characteristic odor. It is slightly soluble in water; very slightly soluble in methanol, in dehydrated alcohol, and in acetone; practically insoluble in n-butyl alcohol, in chloroform, in ether, in ethyl acetate, in n-hexane, in methylene chloride, and in n-propyl alcohol; soluble in dilute hydrochloric acid and in dilute alkali hydroxides.

The molecular formula is C7H7NO3, representing a molecular weight of 153.14. The structural formula is:
PURPOSE:To obtain a cosmetic composition, excellent in hiding power and extensibility with hardly any secondary aggregation of powder particles and especially suitable as a pressed or a pasty cosmetic such as a foundation, a cake color, a lipstick or an eye shadow. CONSTITUTION:A cosmetic composition is obtained by adding 0.005-5wt.% high-molecular weight fibrillated polytetrafluoroethylene-(PTFE) having >=1000000 average molecular weight to powder for the cosmetic. Since the powder particles are entangled with fibrils of the PTFE, secondary aggregation of the powder particles is reduced to improve the product saturation when mixed with a pigment. This composition has advantages as follows: When the composition is used as a solid powdery cosmetic, excellent effects on hiding power and extensibility are exhibited. Pressing properties in molding are improved as compared with those in the case of addition of a low-molecular weight PTFE. The strength and hardness after the molding are increased. Furthermore, suppressing effects on dust after coating are great, etc.
Patients in this group will receive treatment through Motor-relearning programme. Patients will be instructed to perform multiple task like holding object, elbow extension/flexion and multiple movements of shoulder joint. This group will receive MRP for about time duration of 4 weeks,3 days per week,2 hours session per day.
BACKGROUND: Fenestrating a Fontan baffle has been associated with improved perioperative outcomes in patients with univentricular hearts. However, longer-term potential adverse effects remain debated. We sought to assess the impact of a fenestrated Fontan baffle on adverse cardiovascular events including all-cause mortality, cardiac transplantation, atrial arrhythmias, and thromboemboli.
METHODS: A multicentre North American retrospective cohort study was conducted on patients with total cavopulmonary connection Fontan baffle, with and without fenestration. All components of the composite outcome were independently adjudicated. Potential static and time-varying confounders were taken into consideration, along with competing risks.
RESULTS: A total of 407 patients were followed for 10.4 (7.1-14.4) years; 70.0% had fenestration of their Fontan baffle. The fenestration spontaneously closed or was deliberately sealed in 79.9% of patients a median of 2.0 years after Fontan completion. In multivariable analysis in which a persistent fenestration was modelled as a time-dependent variable, an open fenestration did not confer a higher risk of the composite outcome (hazard ratio, 1.18; 95% confidence interval, 0.71-1.97; P = 0.521). In secondary analyses, an open fenestration was not significantly associated with components of the primary outcome: that is, mortality or transplantation, atrial arrhythmias, or thromboemboli. However, sensitivity analyses to assess the possible range of error resulting from imprecise dates for spontaneous fenestration closures could not rule out significant associations between an open fenestration and atrial arrhythmias or thromboemboli.
CONCLUSIONS: In this multicentre study, no significant association was identified between an open fenestration in the Fontan baffle and major adverse cardiovascular events.
Frailty represents an integrative prognostic marker of risk that associates with a myriad of age-related adverse outcomes in older adults. As a concept, frailty can help to target scarce resources and identify subgroups of vulnerable older adults that may benefit from interventions or changes in medical management, such as pursing less aggressive glycaemic targets for frail older adults with diabetes. In practice, however, there are several operational challenges to implementing frailty screening outside the confines of geriatric medicine. Electronic frailty indices (eFIs) based on the theory of deficit accumulation, derived from routine data housed in the electronic health record, have emerged as a rapid, feasible and valid approach to screen for frailty at scale. The goal of this paper is to describe the early experience of three diverse groups in developing, implementing and adopting eFIs (The English National Health Service, US Department of Veterans Affairs and Atrium Health-Wake Forest Baptist). These groups span different countries and organisational complexity, using eFIs for both research and clinical care, and represent different levels of progress with clinical implementation. Using an implementation science framework, we describe common elements of successful implementation in these settings and set an agenda for future research and expansion of eFI-informed initiatives.
Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition involved real-time adaptive gameplay that increased in difficulty as performance increased.
A composition (100) and method of preparing the composition for rapid and effective hemostasis is provided. The composition includes a first agent (110) to induce platelet plug formation, a second (120) to induce vasoconstriction and a third agent (130) for activation of coagulation cascade. The composition comprises of 0.01% to 5 % of chitosan; 0.01% to 0.25 % of potassium aluminium sulphate; and 0.01 % to 0.25 % calcium salt. The clotting time of the composition is in the range of 30s to 140s. A method of preparing the hemostatic composition is further disclosed. The composition is configured to control hemorrhage from oozing and pressured bleeding injury any site in human/animal body.
Ixazomib citrate, 2.97 mg/m\^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
An object of the present invention is to provide a protective composition for gastrointestinal mucosa, for example, for inhibiting occurrence of a gastrointestinal mucosa disorder when an oral drug that induces the gastrointestinal mucosa disorder is taken. The protective composition for gastrointestinal mucosa of the present invention as a resolution for achieving the object is characterized by comprising at least a macromolecular polysaccharide, sodium hydrogen carbonate and/or magnesium carbonate, and a polyhydric alcohol. According to the protective composition for gastrointestinal mucosa of the present invention, sodium hydrogen carbonate or magnesium carbonate foams through contact with a gastric juice in stomach to thereby generate diffusing power for the macromolecular polysaccharide. This power can allow the macromolecular polysaccharide to quickly dissolve or disperse in the gastric juice and allow the macromolecular polysaccharide to effectively exert a gastric mucosa protective action. In addition, the macromolecular polysaccharide dissolved or dispersed in the gastric juice moves into intestine without degradation in stomach, then dissolves in an intestinal juice having a neutral or alkaline pH, and exerts an intestinal mucosa protective action without degradation also in intestine. The polyhydric alcohol plays a role as a dispersion medium for the macromolecular polysaccharide and sodium hydrogen carbonate or magnesium carbonate which are powder, or enables formulation of the protective composition for gastrointestinal mucosa of the present invention into various dosage forms, according to the nature and use amount thereof.
Increased creatine phosphokinase (CPK) occurred in 76% of 74 pediatric patients who received KOSELUGO in SPRINT, including Grade 3 or 4 in 9% of patients. Increased CPK resulted in dose reduction in 7% of patients. Increased CPK concurrent with myalgia occurred in 8% of patients, including one patient who permanently discontinued KOSELUGO for myalgia.

Rhabdomyolysis occurred in an unapproved adult population who received KOSELUGO as a single agent. 

Obtain serum CPK prior to initiating KOSELUGO, periodically during treatment, and as clinically indicated. If increased CPK occurs, evaluate patients for rhabdomyolysis or other causes. Withhold, reduce dose, or permanently discontinue KOSELUGO based on severity of adverse reaction [see Dosage and Administration (2.2)].
In this group subjects receive Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for resVida.
The invention relates to a traditional Chinese medicine prescription for treating duck cholera and discloses traditional Chinese medicine powder for treating duck cholera. The traditional Chinese medicine prescription respectively comprises the following raw medicinal materials: agastache rugosus, herba violae, folium isatidis, honeysuckle stem, garden burnet, houttuynia cordata, Licorice Roots Northwest Origin, scutellaria baicalensis and dandelion. In order to achieve a better using effect, the invention also provides a method for preparing the traditional Chinese medicine powder. The preparation method comprises the following steps: (1) removing impurities in the raw medicinal materials such as the agastache rugosus, herba violae, folium isatidis, honeysuckle stem, garden burnet, houttuynia cordata, Licorice Roots Northwest Origin, scutellaria baicalensis and dandelion, rapidly washing by using cool boiled water, and draining; and (2) airing the raw medicinal materials obtained in the step (1), and grinding into fine powder for later use. The raw medicinal materials used in the traditional Chinese medicine prescription are complementary in drug properties, and mutual inhibition, mutual restraint between two drugs and mutual-detoxication of compatibility of medicines are avoided, so that the medicines are obvious in mutual promotion and mutual-assistance effects and have the effects of clearing away heat and toxic materials, promoting diuresis and stopping dysentery and sterilizing and diminishing inflammation. The traditional Chinese medicine prescription is used for treating duck cholera and has an exact curative effect.
For the past few years, microbial biofilms have been emerging as a significant threat to the modern healthcare system, and their prevalence and antibiotic resistance threat gradually increase daily among the human population. The biofilm has a remarkable impact in the field of infectious diseases, in particular healthcare-associated infections related to indwelling devices such as catheters, implants, artificial heart valves, and prosthetic joints. Bacterial biofilm potentially adheres to any biotic or abiotic surfaces that give specific shelter to the microbial community, making them less susceptible to many antimicrobial agents and even resistant to the immune cells of animal hosts. Around thirty clinical research reports available in PUBMED have been considered to establish the occurrence of biofilm-forming bacteria showing resistance against several regular antibiotics prescribed against infection by clinicians among Indian patients. After the extensive literature review, our observation exhibits a high predominance of biofilm formation among bacteria such as Escherichia sp., Streptococcus sp., Staphylococcus sp., and Pseudomonas sp., those are the most common biofilm-producing antibiotic-resistant bacteria among Indian patients with urinary tract infections and/or catheter-related infections, respiratory tract infections, dental infections, skin infections, and implant-associated infections. This review demonstrates that biofilm-associated bacterial infections constantly elevate in several pathological conditions along with the enhancement of the multi-drug resistance phenomenon.
Analyte sensing and response systems and methods include a sensor detecting one or more analytes in a medium. The sensor uses decoupled transmit and receive elements or antennas to transmit a signal into the medium, and receive a response to the transmitted signal. An action that is based on the detection of the analyte is generated which can directly or indirectly affect the detected analyte in the medium. The action is automatically performed. The action can be increasing or decreasing flow from a source of the analyte, or of a chemical compound interacting with the analyte. An example of the action is controlling an insulin pump, where the analyte is glucose.
The present invention provides a category of aryl-substituted imidazoline-2-ketone derivatives, a compound with a natural product CombretastatinA-4 as a precursor. The imidazoline-2-ketone five-heterocycle is used to substitute ethylene chain to prepare a series of imidazolinone derivative. The imidazolinone derivative is a compound of novel structure. The initial screening tests of pharmacological activity have proved that a plurality of compounds have inhibitory effects on tumor cells in vitro; part of the compounds have significant inhibitory effects; the IC50 has achieved to Mu M level; wherein, the representative compound IVa has significant anti-tumor activity in vivo. The aryl-substituted imidazoline-2-ketone derivatives provided by the present invention and the related salts can be used in preparation of anti-tumor drugs. The present invention is reasonable in design, simple in preparation method and applicable to practical use. The structure of the present invention is the above formula.
Hypersensitivity reactions may occur within a few minutes following the initiation of the infusion of cabazitaxel, thus facilities and equipment for the treatment of hypotension and bronchospasm should be available. Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.

Premedicate all patients prior to the initiation of the infusion of cabazitaxel [see Dosage and Administration (2.1)] . Observe patients closely for hypersensitivity reactions, especially during the first and second infusions. Severe hypersensitivity reactions require immediate discontinuation of the cabazitaxel infusion and appropriate therapy. Cabazitaxel is contraindicated in patients with a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80 [see Contraindications (4)] .